| INTRODUC TI ON
Correct classification of haemophilia A severity is important as treatment intensity is based on categorization.
1 Severe (factor VIII [FVIII] activity levels <0.01 IU/mL) and some moderate (FVIII activity levels 0.01-0.05 IU/mL) haemophilia patients receive prophylactic replacement therapy to prevent spontaneous bleeding in joints and muscles while mild haemophilia A patients (FVIII activity levels 0.05-0.40 IU/ mL) receive desmopressin or replacement therapy only in cases of trauma and/or surgery. 1, 2 Measuring FVIII activity levels accurately and reproducibly in different laboratories is therefore essential. We recently showed that despite excellent performance in the ECAT external quality assessment programme, between-laboratory variation may result in different FVIII levels, and consequently, in misclassification of haemophilia severity. 4 Limited between-laboratory variation in FVIII activity levels is also of importance for the monitoring of treatment in patients with haemophilia A, as specific target FVIII activity levels should be maintained around surgery and bleeding episodes. 1, 2, 5 Two assays are widely used to measure FVIII activity: the onestage assay (OSA) and the two-stage chromogenic substrate assay (CSA). Most laboratories use the OSA, which is based on the activated partial thromboplastin time (APTT), using the time until clot formation as its endpoint. 6 In the CSA, the coagulation system is triggered resulting in the generation of factor Xa (FXa). 7 In the second step of this test, FXa hydrolyses a chromogenic substrate causing a colour change, which reflects the amount of FVIII activity left in the patient sample. The endpoint in the CSA differs from that in OSA, as the CSA measures extinction at a plateau phase.
Discrepancies in FVIII activity levels have been extensively reported between these two assays, depending on the mutation in F8 gene. 8, 9 Nowadays, reagents and equipment to perform FVIII activity measurements are widely available. The use of varying products may partially explain the between-laboratory variation in FVIII results.
However, it is still unclear what the precise impact is of varying in reagents and equipment on the variability of FVIII activity measurements. 11, 12 A possible explanation may be that particular companies provide the majority of products applied for the haemostatic testing which is standard in haemophilia. Most reports focus on the specific reagents of one company, 12, 15, 16 rather than analysing a test system from one company which consists of calibrator, activator, deficient plasma and equipment. As this is often the case in real life situations, causal factors leading to the variation in FVIII activity levels should be investigated more extensively.
To improve quality of measurements in haemostasis laboratories, laboratories follow international guidelines and participate in external quality control surveys. The data from the ECAT external quality assessments indeed show that laboratories use all components for the FVIII assays from one company in a majority of cases. Therefore, ECAT data are highly suitable to investigate the influence of company set-ups on FVIII activity level variation. 
| Impact of test system on FVIII activity levels in the CSA
The impact of different test systems in the CSA was also investigated. FVIII activity levels were compared between Chromogenix
Coamatic, Hyphen Biomed and a test system from Siemens in the four plasma samples as described under the subheading of "Impact of test system on FVIII activity levels in the OSA." The Kruskal-Wallis test was performed to analyse the data.
| Contribution of deficient plasma and calibrator
As not all laboratories use complete packages from one manufacturer, deficient plasma or a calibrator from another company may explain the variation in FVIII results. Unfortunately, this could not be investigated in the ECAT surveys, as most laboratories use all the components in the test system from one company. For this reason, we varied in deficient plasma on three different machines and its reagents as shown in Table 1 . Calibration curves were created in these set-ups. Using these calibration curves, FVIII activity levels were measured in duplicate in three samples; one sample with normal FVIII activity levels (consensus value FVIII 1.00 IU/mL), mild haemophilia A (consensus value FVIII 0.34 IU/mL) and moderate haemophilia A (consensus value FVIII 0.04 IU/mL).
The influence of the calibrator was investigated by measuring the FVIII activity levels in duplicates from the calibrator of Werfen (HemosIL Cal Plasma) and Stago (STA-CK Prest) in the Siemens setup as described in Table 1 . As these calibrators have assigned values, we compared the measured FVIII activity levels of the calibrators with their assigned values.
| RE SULTS

| Quantifying variation in FVIII activity measurements
In 
| Impact of test system on haemophilia severity classification
The impact of this FVIII variability on haemophilia classification which is solely based on FVIII activity levels is significant. This is illustrated by the fact that the severe haemophilia A sample was classified as moderate in 37/139 (26.6%) of all OSA measurements ( Figure 2D ). TA B L E 1 Set-up of the different packages when varying in deficient plasma 
When classification is differentiated according to company in samples
F I G U R E 1
| Impact of test system on FVIII activity levels in the OSA
Factor VIII activity levels were analysed for the three major companies and shown in Figure 3 . In a sample from a healthy person ( Figure 3A) , FVIII activity levels measured with products from Werfen (median 0.93, IQR 0.88-0.98 IU/mL) were lower than FVIII activity levels measured by products from Stago (median 1.07, IQR 1.02-1.14 IU/mL) or Siemens (median 1.03, IQR 0.97-1.07 IU/ mL). We also observed this trend in a sample with 0.42 IU/mL FVIII ( Figure 3B ). The differences between the three manufacturers in the samples with lower FVIII activity levels were minimal; however, small differences may have a large clinical impact.
We also investigated the influence of different activators in the set-up of all products from Siemens. This company had an activator based on ellagic acid and one based on silica. In addition, phospholipid concentrations differ between these activators. We were able to compare these activators since enough participants in the ECAT survey used these activators. We observed equal FVIII activity values between the activators in all four plasma samples ( Figure S1 ).
| Impact of test system on FVIII activity levels in the CSA
For the CSA, three kits were most oftenly used: (a) Chromogenix Coamatic (n = 8-13), (b) Hyphen Biomed (n = 14-23) and (c) FVIII Chromogenic assay from Siemens (n = 7-10). We compared the FVIII activity levels obtained by the three most commonly used kits and observed no consistent differences in FVIII activity levels between the kits (Figure 4 ). Some small differences were found as the kit from
Siemens had higher FVIII activity levels in the normal sample (median 1.02, IQR 0.98-1.09 IU/mL) compared to the kit from Hyphen Biomed (median 0.94, IQR 0.88-0.98 IU/mL).
| Effect of deficient plasma on FVIII activity
A possible explanation for the variation in the OSA may be variation in the behaviour of the deficient plasma. Deficient plasma was therefore also exchanged between company set-ups. We observed that using deficient plasma from another company did not influence FVIII activity levels in samples of a moderate haemophilia A patient or in samples containing FVIII activity levels around 0.40 IU/mL FVIII ( Figure 5 ). However, in a sample from a healthy person, Stago deficient plasma causes slightly lower FVIII results. For example, the FVIII activity level in a Siemens set-up using Stago deficient plasma results in a FVIII level of 1.00 IU/mL, while Siemens deficient plasma 
| Differences in calibrator
The influence of the calibrator was determined by measuring the FVIII activity in each calibrator and comparing the measured FVIII activity value to the assigned value from the manufacturer, based on the WHO international standard. The FVIII levels in both the STA-Unicalibrator and the HemosIL calibrator plasmas were measured in duplicates on the Siemens set-up as described in Table 1 .
The assigned calibration value was 1.10 and 0.98 IU/mL for the STAUnicalibrator and the HemosIL, respectively, while the measured FVIII activity levels of these calibrators were 1.21 and 1.12 IU/mL.
As these values differed from the assigned value, it may be that the calibrator is one of the causes that results in the variation in FVIII activity measurements.
| D ISCUSS I ON
The aim of this study was to quantify and understand in more detail the variation in FVIII activity measurements when testing by This may be due to the fact that Verbruggen et al showed the CVs for samples with FVIII activity levels between 0.10-0.20 IU/mL and not lower. Furthermore, it may be that that haemophilia treatment centres may be more accurate in general and may more often perform both OSA and CSA. A subanalysis was performed comparing the variability of the two assays with the data from centres carrying out both assays, and no difference in CV was observed ( Figure   S2 ). The CV increases substantially in samples with low FVIII activity levels (Figure 1 ), although absolute differences in FVIII activity levels remain small. Therefore, it is important to realise, that although these differences are small, they have significant clinical consequences as early initiation of prophylactic treatment is largely dependent on test results and subsequent classification of haemophilia severity. Stago in a Siemens set-up. Despite the fact that small differences were found, results should be interpreted with caution. In general, a small amount of factor concentrate may still be present in plasma samples derived from severe haemophilia A patients due to prior treatment and an insufficient wash out period, thus influencing FVIII activity levels. In addition, the metrological traceability is only based on a consensus model and no golden standard is available for FVIII measurements. This again raises the question how to perform haemophilia classification based on the measured FVIII levels as it is still unclear which FVIII activity assay is most optimal.
Another cause for the variation in OSA FVIII measurements may be the calibrator. As we found a higher FVIII activity value of the haemophilia A patients which may also have influenced the FVIII activity levels found in this study.
12
High between-laboratory CVs may influence diagnoses of haemophilia A patients between hospitals as reported previously. reduce the large between-laboratory CV both in the OSA and CSA, standardization is required for example by an external quality control as the ECAT foundation. Current developments in method harmonization may also reduce the large between-laboratory variability.
In conclusion, FVIII activity levels are negatively associated with CV for both the OSA and CSA. The variation in the OSA may be attributed to the different components used in current FVIII assays.
As no golden standard is available for FVIII measurements, it is not possible to judge which result is superior. Future studies focusing on standardization of FVIII measurements and in-depth education on available tests are required to further improve haemophilia diagnosis and patient management.
ACK N OWLED G EM ENTS
W. van Loenen (Amphia Hospital, Breda, the Netherlands) and A. 
